Related Experiment Video
Updated: Jul 15, 2026

Automation of Bio-Atomic Force Microscope Measurements on Hundreds of C. albicans Cells
Published on: April 2, 2021
The pharmacology and clinical use of caspofungin
William W Hope1, Shmuel Shoham, Thomas J Walsh
1National Institutes of Health, 10 Center Dr, Bethesda, MD, 20892, USA.
Abstract:
Caspofungin was the first echinocandin to be licensed for the treatment of invasive fungal infections. Caspofungin has in vitro and in vivo activity against Candida spp. and Aspergillus spp., which constitute the majority of medically important opportunistic fungal pathogens. Caspofungin inhibits the synthesis of the 1,3-beta-glucan, with resultant osmotic instability and lysis. The pharmacology of caspofungin is relatively complex. Trafficking of drug into tissues is an important determinant of the shape of the concentration-time relationship. Caspofungin has demonstrated efficacy in experimental models of invasive candidiasis and aspergillosis, which reflect its activity in the treatment of oropharyngeal, esophageal and disseminated candidiasis, as well as salvage therapy for patients with invasive aspergillosis.
Related Concept Videos
Antifungal Agents
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
Cryptococcal Meningitis
Candidiasis
Overview of Fungi
Fungal Phylum Ascomycota

